COSCIENS Biopharma Inc. (CSCI)
NASDAQ: CSCI · Real-Time Price · USD
3.750
+0.190 (5.34%)
Nov 4, 2024, 4:00 PM EST - Market closed
COSCIENS Biopharma Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 4.92 | 4.5 | 5.64 | 5.26 | 3.65 | 0.53 | Upgrade
|
| Revenue Growth (YoY) | -43.63% | -20.25% | 7.22% | 44.03% | 586.47% | -98.02% | Upgrade
|
| Cost of Revenue | 0.9 | 0.22 | 0.16 | 0.09 | 2.32 | 0.41 | Upgrade
|
| Gross Profit | 4.01 | 4.28 | 5.48 | 5.17 | 1.34 | 0.12 | Upgrade
|
| Selling, General & Admin | 7 | 8.72 | 8.23 | 7.27 | 5.89 | 7.83 | Upgrade
|
| Research & Development | 15.04 | 13.56 | 12.51 | 6.57 | 1.51 | 1.84 | Upgrade
|
| Other Operating Expenses | - | - | 0.12 | - | -0.14 | 0.17 | Upgrade
|
| Operating Expenses | 22.04 | 22.28 | 20.86 | 13.84 | 7.26 | 9.84 | Upgrade
|
| Operating Income | -18.02 | -18.01 | -15.38 | -8.67 | -5.93 | -9.71 | Upgrade
|
| Interest Expense | -0.01 | -0.01 | -0 | -0.01 | -0 | -0.59 | Upgrade
|
| Interest & Investment Income | 1.13 | 1.13 | - | - | - | - | Upgrade
|
| Currency Exchange Gain (Loss) | -0.16 | -0.21 | 0.88 | 0.22 | 0.57 | 0.09 | Upgrade
|
| Other Non Operating Income (Expenses) | 1.8 | - | 0 | -0.01 | 0.42 | 4.52 | Upgrade
|
| EBT Excluding Unusual Items | -15.27 | -17.1 | -14.5 | -8.48 | -4.94 | -5.7 | Upgrade
|
| Merger & Restructuring Charges | -4.08 | - | - | - | - | -0.51 | Upgrade
|
| Impairment of Goodwill | - | - | -7.64 | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.55 | 0.55 | - | - | - | - | Upgrade
|
| Asset Writedown | - | - | -0.58 | - | - | -0.02 | Upgrade
|
| Other Unusual Items | - | - | - | - | 0.22 | - | Upgrade
|
| Pretax Income | -18.8 | -16.55 | -22.73 | -8.48 | -4.72 | -6.23 | Upgrade
|
| Income Tax Expense | -0.57 | - | - | -0.11 | 0.4 | -0.19 | Upgrade
|
| Earnings From Continuing Operations | -18.23 | -16.55 | -22.73 | -8.37 | -5.12 | -6.04 | Upgrade
|
| Net Income | -18.23 | -16.55 | -22.73 | -8.37 | -5.12 | -6.04 | Upgrade
|
| Net Income to Common | -18.23 | -16.55 | -22.73 | -8.37 | -5.12 | -6.04 | Upgrade
|
| Shares Outstanding (Basic) | 1 | 1 | 1 | 1 | 0 | 0 | Upgrade
|
| Shares Outstanding (Diluted) | 1 | 1 | 1 | 1 | 0 | 0 | Upgrade
|
| Shares Change (YoY) | 7.69% | - | 5.63% | 179.74% | 134.83% | 2.70% | Upgrade
|
| EPS (Basic) | -13.94 | -13.63 | -18.72 | -7.28 | -12.46 | -34.54 | Upgrade
|
| EPS (Diluted) | -13.94 | -13.63 | -18.72 | -7.28 | -12.46 | -35.00 | Upgrade
|
| Free Cash Flow | -19.92 | -17.14 | -13.69 | -8.61 | -4.13 | -10.73 | Upgrade
|
| Free Cash Flow Per Share | -15.24 | -14.12 | -11.28 | -7.49 | -10.05 | -61.30 | Upgrade
|
| Gross Margin | 81.67% | 95.06% | 97.22% | 98.29% | 36.56% | 22.93% | Upgrade
|
| Operating Margin | -366.71% | -400.36% | -272.64% | -164.85% | -162.24% | -1825.75% | Upgrade
|
| Profit Margin | -370.91% | -367.99% | -402.96% | -159.09% | -140.14% | -1135.71% | Upgrade
|
| Free Cash Flow Margin | -405.31% | -380.99% | -242.75% | -163.71% | -113.06% | -2015.98% | Upgrade
|
| EBITDA | -17.99 | -17.99 | -15.36 | -8.53 | -5.69 | -9.4 | Upgrade
|
| EBITDA Margin | - | - | -272.36% | -162.09% | -155.89% | - | Upgrade
|
| D&A For EBITDA | 0.03 | 0.02 | 0.02 | 0.15 | 0.23 | 0.32 | Upgrade
|
| EBIT | -18.02 | -18.01 | -15.38 | -8.67 | -5.93 | -9.71 | Upgrade
|
| EBIT Margin | - | - | -272.64% | -164.85% | -162.24% | - | Upgrade
|
| Revenue as Reported | - | - | - | - | - | 0.53 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.